Wei R, Ma S, Wang C, Ke J, Yang J, Li W, et al
While evidence suggests GLP-1 receptor agonists have protective effects against arterial disease, the evidence specifically examining venous thrombosis risk is more limited, though no safety signals have emerged
In addition, we also found that the clinical rationale and protocol design of the TEXAIS (Treatment With Exenatide in Acute Ischemic Stroke) trial (Trial registration: ClinicalTrials.gov/ANZCTR NTA1127 and ACTRN12614001189617) (108, 109)
95% CI, 0.86-1.05) and all-cause mortality (HR = 1.04
95% CI, 1.13-1.22)
Metabolism refers to the sum of reactions that occur in cells to provide the body with energy